In the lead-up to next year’s 13th International Congress on Schizophrenia Research in Colorado Springs, Colorado, SRF and the ICOSR will host a series of live discussions on topics of high current interest. This summer we will focus on research that is especially relevant to the clinic with, first, a discussion on the period before or just after the diagnosis of schizophrenia. Later this summer we will take up the topic of comorbidities, specifically schizophrenia and addictive disorders.
ICOSR co-director S. Charles Schulz of the University of Minnesota led a panel that included Barbara Cornblatt of the Albert Einstein College of Medicine, John Kane of North Shore University Hospital and Long Island Jewish Medical Center, Andrea Auther of the Zucker Hillside Hospital, and Michael O’Sullivan of the University of Minnesota in the discussion of recent and current research on the early stages of schizophrenia. This discussion was held in conjunction with the Schizophrenia International Research Society and the International Prodromal Research Network, which will host the Psychosis Satellite Meeting at ICOSR 2011.
L. Kola Oyewumi — Posted 28 July 2010
Don Linszen — Posted 28 July 2010
S. Charles Schulz
Recent years have seen substantial attention focused on the early stages of schizophrenia with a major motivation of understanding the illness before long-term effects of medication treatments and chronicity of illness. As first-episode programs emerged, there came a greater recognition of the clinical utility of early intervention. Examination of the impact of duration of untreated psychosis (DUP) led to a substantial focus on the possibility of diminishing poor outcome in young people with the illness. As the movement in the early stages of schizophrenia through first-episode programs progressed, many clinicians began examining the prodrome—non-specific symptoms preceding the onset of the illness. Work around the world has examined the possibility of psychosocial, nutraceutical, or pharmacologic interventions to diminish prodromal symptoms and even to perhaps forestall the onset of serious psychiatric illness. The purpose of the Webinar presentation will be to examine prodromal programs—including family interventions, to describe a new NIMH-funded trial designed to examine the impact of specific multimodal interventions compared to treatment as usual, and to close with an exploration of recent first-episode brain imaging and neuropsychological testing in the first episode as well as a discussion of family interventions at this stage of disease.
Barbara Cornblatt is director of the RAP (Recognition and Prevention) Program at The Zucker Hillside Hospital, which is a combined treatment and research center. Research focuses on the identification of early biomarkers and risk factors in at-risk adolescents and young adults that predict future psychosis, especially schizophrenia. Prevention of psychosis is the long-range treatment goal of the program. Selection and evaluation of potential treatments are based on research findings, and both pharmacological and psychosocial treatment strategies are currently under study. The program is based on a neurodevelopmental framework, suggesting that there are several different prodromal stages and that treatment should be tailored to the specific needs of the patients, which may differ considerably, depending on whether they are in the early or late stages of the prodrome. In this context, family-focused therapy has several advantages that will be discussed by Andrea Auther, who is the co-director of the RAP Program’s clinical component.
John Kane, Chair of Psychiatry at The Zucker Hillside Hospital, has been involved in the treatment and research of first-episode patients for over two decades. He and his colleagues have reported on the psychobiological characteristics of the first episode and have also published extensively on both short and long-term pharmacologic treatment. Kane now heads a large NIMH-funded intervention study in first-episode schizophrenia and will describe the background and goals of this research.
Charles Schulz, Head of the Department of Psychiatry at the University of Minnesota Medical School, has a long-held interest in the early stages of schizophrenia, beginning with his work with imaging in adolescents with the illness. In this Webinar, Schulz will discuss a multimodal MRI sequence performed in a pilot study with the MIND Research Network to examine differences between first-episode patients and controls, as well as to patients who have had the illness for many years. His colleague, Michael O’Sullivan, will discuss the utility of family psychoeducation to help support parents whose son or daughter has come down with the illness. He will present information on the parents’ response to treatment.
At the conclusion of the Webinar, Schulz, Kane, and Cornblatt will briefly discuss organizations related to their work and the goals of their societies and meetings.